Navigation Links
New Positive Pre-clinical Data for Active Biotech's RA Project I-3D

LUND, June 15, 2007-Active Biotech (OMX Nordic: ACTI) presented pre-clinical results for the project I-3D at the annual EULAR (The European League Against Rheumatism, www.eular.org ) conference, June 13-16*.

"The new pre-clinical data presented show that I-3D has a significant inhibitory effect on disease development in an experimental model for rheumatoid arthritis (RA)", commented Sven Andréasson, President & CEO Active Biotech.

An additive inhibitory effect on disease development is achieved when I-3D is combined with methotrexate, an anti-proliferative drug widely used for the treatment of various inflammatory disorders and cancer.

The results strengthen further clinical development of I-3D as monotherapy or in combination with methotrexate.

Lund, June 15, 2007

Active Biotech AB (publ)

Sven Andréasson President and CEO

About I-3D The I-3D compound is a novel small molecule inhibitor of human dihydroorotate dehydrogenase (DHODH). Inflammatory diseases such as RA involve rapidly proliferating T cells with an exceptional requirement for de novo pyrimidine biosynthesis. DHODH inhibition results in inhibition of de novo pyrimidine synthesis and thereby inhibition of T-cell proliferation.

In May 2006, Active Biotech and Chelsea Therapeutics International Ltd (NASDAQ:CHTP) signed an agreement for the co-development and commercialization of I-3D. Under the agreement, Active Biotech and Chelsea will jointly conduct and fund the clinical development of the I-3D portfolio.

A candidate drug is planned to be selected this year for further clinical trials in 2008.

*For further information and to view the complete poster "ABR-224050: a novel dihydroorotate dehydrogenase inhibitor suppressing disease development in collagen induced arthritis", please visit www.activebiotech.com.

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics International Ltd.

Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 20 50


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/7/2017)... RANCHO MIRAGE, Calif. , Sept. 7, 2017  For nearly two ... and service in the Assisted Reproduction Insurance industry. Today, New Life Agency ... expensive fertility medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/6/2017)... Sept. 6, 2017  Robert G. Szewc, M.D., is ... Member in recognition of his contributions to the Medical ... a Nephrologist at the practice of Kidney and Hypertension ... care and hypertension solutions. He has worked in this ... career experience, as well as expertise in kidneys, hypertension, ...
Breaking Medicine Technology:
(Date:9/22/2017)... Overland Park, KS (PRWEB) , ... September 22, ... ... to Insulate Plus, a nutritional supplement produced by Native Remedies that helps promote ... a top priority for many individuals. However, some prescription-based approaches can have negative ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... brush more effectively even on the go. Their electric toothbrushes aggressively attack oral ... inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a premium ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... more products at customers’ doorstep. According to Smart Mart, customers can now order ... to offer wearable, and customers can find clothing at discounted prices. Apart from ...
(Date:9/21/2017)... ... 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a stylistic ... from up to two layers of subject matter along with fully customizable backdrop animation, ... Final Cut Pro X. , With ProSlideshow Portrait each user are given the ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about ... 11 to the end of November. , The Chicago, Illinois, based self-defense brand has ... teach them about the ease of taking their personal safety into their own hands. ...
Breaking Medicine News(10 mins):